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Abstract
Background: There is a strong link between antibiotic consumption and the rate of antibiotic resistance. In Australia,
the vast majority of antibiotics are prescribed by general practitioners, and the most common indication is for acute
respiratory infections. The aim of this study is to assess if implementing a package of integrated, multifaceted
interventions reduces antibiotic prescribing for acute respiratory infections in general practice.
Methods/design: This is a cluster randomised trial comparing two parallel groups of general practitioners in
28 urban general practices in Queensland, Australia: 14 intervention and 14 control practices. The protocol was
peer-reviewed by content experts who were nominated by the funding organization.
This study evaluates an integrated, multifaceted evidence-based package of interventions implemented over a six
month period. The included interventions, which have previously been demonstrated to be effective at reducing
antibiotic prescribing for acute respiratory infections, are: delayed prescribing; patient decision aids; communication
training; commitment to a practice prescribing policy for antibiotics; patient information leaflet; and near patient
testing with C-reactive protein.
In addition, two sub-studies are nested in the main study: (1) point prevalence estimation carriage of bacterial
upper respiratory pathogens in practice staff and asymptomatic patients; (2) feasibility of direct measures of
antibiotic resistance by nose/throat swabbing.
The main outcome data are from Australia’s national health insurance scheme, Medicare, which will be accessed
after the completion of the intervention phase. They include the number of antibiotic prescriptions and the
number of patient visits per general practitioner for periods before and during the intervention. The incidence of
antibiotic prescriptions will be modelled using the numbers of patients as the denominator and seasonal and
other factors as explanatory variables. Results will compare the change in prescription rates before and during
the intervention in the two groups of practices.
Semi-structured interviews will be conducted with the general practitioners and practice staff (practice nurse
and/or practice manager) from the intervention practices on conclusion of the intervention phase to assess the
feasibility and uptake of the interventions.
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An economic evaluation will be conducted to estimate the costs of implementing the package, and its cost-
effectiveness in terms of cost per unit reduction in prescribing.
Discussion: The results on the effectiveness, cost-effectiveness, acceptability and feasibility of this package of
interventions will inform the policy for any national implementation.
Trial registration: The GAPS trial is registered under the Australian New Zealand Clinical Trials Register, reference
number: ACTRN12615001128583 (registered 26/10/2015).
Keywords: General practice, Primary care, Antimicrobial stewardship, Antibiotics, Antimicrobial resistance, Protocol
Background
Australia is one of the highest consumers of antibiotics
in the developed world with 45 % of the Australian
population being supplied at least one antibiotic per year
[1]. The defined daily dose (DDD) in Australia is nearly
23/1000 population/day [1] compared with about 18
DDD/1000 population /day in Denmark and less than 11
DDD/1000 population /day in general practice in the
Netherlands [2–4].
There is a strong link between antibiotic consumption
and the rate of antibiotic resistance [5]. Acute respira-
tory tract infection (ARIs) are the most common reason
for prescribing an antibiotic in primary care [6]. In
Australia antibiotic resistance in common pathogens
causing ARIs has increased over the past 20 years [7].
For example, resistance of Streptococcus pneumoniae to
macrolide antibiotics has increased from 8.7 % in 1994
to 20.4 % in 2007, and this trend is continuing [8]. Patients
with infections caused by antibiotic-resistant organisms
have an increased mortality compared with those infected
with antibiotic-susceptible organisms [9, 10].
General Practitioners (GPs) have the potential to be
the most influential health care professionals to address
the problem of antibiotic resistance as the majority of
antibiotics are prescribed in the general practice setting
and antibiotics remain the most common class of medicine
prescribed [11]. Continued improvements in prescribing
practice and a positive influence on individual and commu-
nity beliefs about antibiotic consumption are essential to
limit the spread of antibiotic resistance [12]. Antibiotics are
often inappropriately prescribed for patients with ARIs [6].
Research shows that up to half of antimicrobials prescribed
in Australian hospitals are discordant with guidelines or
microbiological results and hence are considered inappro-
priate,[13] however, little is known about what happens in
the primary care setting [14].
Unfortunately, new antimicrobials are not being de-
veloped at a pace that comes anywhere close to meet-
ing the urgent need; therefore, the healthcare system
needs to undertake efforts that save one of medicine’s
most precious and long-standing resources [15]. This
was summarised by the World Health Day 2011 slogan
‘Combat antibiotic resistance: no action today, no cure
tomorrow’. Reducing the inappropriate use of antimi-
crobials has been shown to improve patient outcomes
and reduce adverse consequences of antibiotic use (in-
cluding antibiotic resistance, toxicity and unnecessary
costs) [16].
Antimicrobial stewardship (AMS) is the coordinated
actions designed to promote and increase the appropriate
use of antimicrobials and is a key strategy to conserve
the effectiveness of antibiotics. Australia’s first National
Antimicrobial Resistance strategy for 2015–2019 states
that there is a need for resources to support the imple-
mentation of AMS for all settings including primary
health care [17].
There are a number of interventions that have shown
promise at decreasing antibiotic prescribing for ARIs
in primary care: delayed prescribing; patient decision
aids; communication training; near patient testing
with C-reactive protein and commitment to a practice
prescribing policy for antibiotics [18–20]. Prescribers
are well placed to convey the importance of informing
patients that they are twice as likely to carry resistant
bacteria after a course of antibiotics as someone who has
not taken them [21–23]. Evidence from general practice
demonstrates that patient satisfaction is linked more
with good communication than a prescription for an
antibiotic [24, 25]. Several studies have demonstrated
that GPs trained in communication skills, [26, 27] and
specifically in Shared Decision Making [28–30], pre-
scribed antibiotics significantly less than GPs without
training. The benefits of patients managed by a GP
trained in enhanced communication skills can persist
for at least 3 years, and do not appear to compromise
repeat consultation rate, patient recovery or patient satis-
faction [26, 27, 31, 32].
Many of these strategies have not been adopted in
Australia so there is no evidence about their efficacy in
this context, and all have been evaluated in isolation.
Evidence from other areas of healthcare suggests that
using multiple strategies or interventions in concert
could have an even greater impact on prescribing behav-
iour and induce longer term behaviour change. This could
enable clinicians and health care systems to reduce anti-
microbial resistance in the future [33].
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Aim
The aim of our study is to assess if implementing an in-
tegrated, multifaceted package of interventions reduces
antibiotic prescribing for ARIs in general practice.
Sub-studies nested within the main study
Two specific studies are nested in the main study:
1. point prevalence estimation carriage of bacterial
upper respiratory pathogens in practice staff and
asymptomatic patients
2. feasibility of direct measures of antibiotic resistance
by nose/throat swabbing.
Primary objective
Our primary objective is to assess the effectiveness, of
an integrated, multifaceted package of interventions for
ARIs in general practice.
Secondary objectives are
1. to assess the feasibility and uptake of the integrated
package of interventions for ARIs.
2. to assess the likely costs and cost-effectiveness of
implementing the integrated package of interventions
for ARIs.
3. to estimate the prevalence of bacterial upper
respiratory pathogens in asymptomatic general
practice staff and patients
4. to assess the feasibility of direct measures of
antibiotic resistance by nose/throat swabbing.
Methods
The trial protocol was developed by researchers at the
University of Queensland, Bond University and Queensland
University of Technology in Australia in accordance with
the CONSORT statement extension to cluster randomised
trials [34].
Study design
This is a clustered randomised parallel group controlled
trial.
Study setting
This study is being conducted in South East Queensland,
Australia. Twenty-eight urban general practices have been
purposely recruited and randomised to either the control
or intervention group.
Eligibility criteria
All GPs from the recruited general practices were eli-
gible to participate in the study provided they gave
consent for the research team to obtain their data on
antibiotic prescribing and patient visits from Medicare.
General practice staff and patients attending the GP
practice for consultation with non-infectious complaints
were eligible for the point prevalence nose and throat
swab study: asymptomatic carriage of bacterial upper re-
spiratory pathogens.
Implementation of interventions
An integrated, multifaceted package of interventions will
be implemented in the intervention practices by research
coordinators who have been trained in the use of the in-
terventions. The GPs in the control practices will con-
tinue normal clinical practice while the GPs in the
intervention practices will be trained in the interventions
as described below. In the six month study period, the
research coordinators will regularly visit the intervention
practices to support uptake of the interventions and pro-
vide any necessary supplementary training.
Interventions
Evidence based interventions already demonstrated to be
effective at reducing antibiotic prescribing for ARIs else-
where in the world were selected [33]. They were com-
bined into an integrated, multifaceted package with the
following components:
1. Poster on Practice Antibiotic Prescribing Policy
This intervention consists of displaying a poster-sized
prescribing policy in the GPs waiting room and/or
examination room. GPs are encouraged to insert their
photograph as endorsement on the poster. The poster,
written at the eighth grade reading level in English
emphasises the GPs’ commitment to guidelines, i.e.
Therapeutic Guidelines: Antibiotic, [35] for appropriate
antibiotic prescribing and explains why antibiotics are
not appropriate in many cases [18].
2. Patient information leaflet
The leaflet provides information to the patient
about inappropriate use of antibiotics for ARIs and
the potential harmful effects of antibiotics. It
complements the poster in the GPs waiting room
and/or examination room.
3. Online communication training package
An online communication module is offered in
combination with background information on the
problem of antimicrobial resistance in primary care
and the effectiveness of antibiotics for most commonly
presenting ARIs. The module is based on the GRACE
INTRO study [19] and has been adapted carefully for
the Australian context as part of the Changing the
Antibiotic Prescribing of General Practice (ChAP
study) (https://www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?id=366836&isReview=true), a
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controlled trial funded by Therapeutic Guidelines Ltd
(http://www.tg.org.au/index.php?sectionid=505).
The online communication training is targeted at
GPs rather than patients, and is developed to be
sensitive to cultural and national differences. The
training in enhanced communication skills focuses
on exploring patients’ concerns and expectations,
providing information on symptoms, natural course of
the disease, treatments, agreement of a management
plan, summing up, and providing guidance about
when to re-consult. GPs are also provided with a
booklet [36] for use during consultations that includes
information on symptoms, use of antibiotics that are
concordant with Therapeutic Guidelines: Antibiotic
[35] and antibiotic resistance, self-help measures, and
when to re-consult. The training is supported by video
demonstrations of consultation techniques and is
offered as a Continuing Professional Development
activity to GPs.
4. Delayed antibiotic prescribing
The GP can offer the patient a delayed antibiotic
prescription. This consists of advice to the patient to
only fill the prescription at a pharmacy after a few
days if symptoms are not starting to settle or
become more severe [37]. A sticker is made available
to GPs to apply to the prescription, labelling it as a
delayed prescription.
5. Patient Decision Aids
A brief graphical laminated summary of evidence for
the management of a number of ARI conditions is
provided as a decision aid for use during the
consultation. These decision aids have been
developed to assist GP and patient to make an
appropriate decision about the management of the
condition. The Patient Decision Aids support the
following conditions:
 acute sore throat;
 acute rhinosinusitis
 acute otitis media; and
 acute bronchitis
6. Near patient testing: CRP study
The CRP test is widely used in some European
primary care settings [38] and has been shown to
significantly reduce antibiotic prescribing for
patients with ARIs [39].
The intervention practices will each have access to a
CRP testing machine for three months (with 50 CRP
tests per practice provided free of charge) to determine
the feasibility and uptake of this type of near patient
testing.
Tests will be performed using the QuikRead CRP
kits (Orion Diagnostica). The research co-ordinator,
in conjunction with the distribution company
(ABACUS ALS), will train the GPs and practice
staff in the use and interpretation of the tests. In
addition GPs will have access to an online training
module on CRP testing (http://gaps.uq.edu.au).
The following instructions will be provided regarding
CRP testing:
 CRP testing should only be used within ARI
consultations for lower respiratory tract
infections and acute rhinosinusitis.
 The GP can decide to perform a CRP test as a
complement to the routine consultation
(including history and physical examination).
 The CRP test is performed on a finger prick
blood sample and the result will be available
within a few minutes.
 The CRP test result can be used in addition to
the clinical assessment to decide whether to
prescribe an antibiotic.
Sample size
The sample size calculation for this study was based on
the average change in antibiotic prescription rates in
practices in the intervention group (before – after the
intervention) compared to the average change in prac-
tices in the control group over the same period. For ex-
ample, an average change in antibiotic prescription rate
from 40 to 20 % in the intervention practices and no
change in the control practices would result in a difference
of 0.2 between the two groups. A difference in average
change in rates in the range 0.20–0.25, if the standard de-
viation in rates was about 0.2, was considered clinically
significant and plausible. With equal numbers of practices
in the two groups, power of 80 %, significance level of 5 %
for a two tailed test, for a difference of 0.24, 12 practices
per group would be needed. In fact 14 practices per group
were recruited so that a difference of 0.22 would be
detectable.
Recruitment
General practitioners who have consented to participate
in the study have been recruited from the selected general
practices. General practice staff and patients attending the
recruited GP practices for consultation with non-infectious
complaints and who have consented to the point preva-
lence study of asymptomatic carriage of bacterial upper re-
spiratory pathogens have also been recruited.
Randomisation
Practices were randomly assigned to either the interven-
tion or control arm in a 1:1 ratio. A blocked randomisa-
tion list with 8 practices per block was generated using
the online software package Sealed Envelope Ltd. 2015
available from: https://www.sealedenvelope.com/simple-
randomiser/v1.
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Data collection
In Australia the universal health insurance scheme,
Medicare, provides access to medical and hospital ser-
vices for all Australian residents and some visitors. It
includes the Medical Benefits Scheme (MBS) which
subsidises the costs of all visits to GPs and medical spe-
cialists in non-hospital settings, and the Pharmaceutical
Benefits Scheme (PBS) which covers almost all medicines.
MBS data include individual records for every patient en-
counter with a GP; GPs are identified by individual provider
codes. PBS data include individual records of every pre-
scription dispensed - from July 2012 this covers all prescrip-
tions, regardless of government subsidies. The prescribing
GP is identified by an individual prescriber number. There
are legislative constraints on linking MBS and PBS records,
but de-identified records can be obtained from the Depart-
ment of Human Services. For all consenting GPs (in the
intervention and control practices) provider records will be
obtained for each patient encounter billed to the MBS and
prescriber records for each prescription reported to the
Pharmaceutical Benefits Scheme (PBS; from July 2012 this
covers all prescriptions, regardless of government subsid-
ies). Data will be requested from July 2012 to the end of the
intervention period. The data will be extracted a month
after the conclusion of the intervention phase in order to
ensure that all records have been submitted Department of
Human Services. Each prescription will be coded using the
Anatomical Therapeutic Chemical (ATC) and those coded
J01 (antibacterial for systemic use) are the outcomes of
primary interest. Prescription rates will be estimated
from the number of antibiotic prescriptions per GP in a
specific period (e.g. day or week) and the number of pa-
tient encounters for that period and GP as the off-set
(i.e., a measure of activity or ‘exposure’).
The cost of the package will be estimated from the
perspective of the public health system at the conclusion
of the intervention phase of the study. All resources
used in implementing the package, including both con-
sumable items and time for all personnel involved, will
be identified. Allocation of GP time and practice specific
items will be estimated based on responses to questions
in the semi-structured interviews. Data on consumables
and all centralised staffing will be measured retrospect-
ively by the project co-ordinator using a pre-developed
costing spreadsheet. Resources invested in any materials
already developed will be considered sunk costs and not
included in the cost of the intervention. Resources used
solely for research and evaluation purposes will also not
be included. Resources will be valued in 2016 Australian
dollars using local market prices and labour costs to give
a total cost of implementation.
We will also estimate the economic value of the change
in antimicrobial usage that results from the package using
PBS list prices. This will be combined with our data on
the cost of implementing the package to provide a meas-
ure of the total changes in costs achieved.
Data analysis
Prescription rates will be estimated using generalised lin-
ear models (e.g., Poisson regression) for the number of
antibiotic prescriptions per GP in a specific period (e.g.,
day or week) with the number of patient encounters for
that period and GP as the off-set (i.e., a measure of ac-
tivity or ‘exposure’). The explanatory variables will be
included in the model to account for: intervention vs
control practices; periods before and during the inter-
vention; and temporal variables to account for secular
trends and seasonal effects. The models will be multi-
level to account for nesting of patients within GPs and
GPs within practices.
Cost-effectiveness of the package will be estimated from
the perspective of the public healthcare system. Results
will be presented as the net cost of implementation and as
the cost per unit reduction in prescription rates. It is un-
clear what Australian decision makers are prepared to pay
for a unit reduction in prescribing so results will be com-
pared to cost-effectiveness estimates published in the
international literature to gauge the efficiency of this pack-
age relative to other approaches used to reduce GP pre-
scribing. Standard sensitivity analyses (one-way and
probabilistic) will be used to explore the robustness of
conclusions to uncertainty in the underlying data.
Semi-structured telephone interviews will be conducted
with the GPs and practice staff, including practice nurses
and/or practice manager, from the intervention practices,
after the intervention phase of the study Questions will
focus on the acceptability and feasibility of the interven-
tions, including the near patient testing (CRP study) in the
practice and perceived impact on the management of ARIs.
Interviews will be conducted after the full package has been
implemented. All interviews will be recorded digitally and
transcribed verbatim by the interviewer. Interview data will
be analysed using inductive thematic analysis. Two re-
searchers will independently code the interviews, compare
their coding and discuss discrepancies. The final thematic
framework will be constructed through an iterative process
and tested by researchers with clinical expertise.
Sub-studies
Specific studies are nested in the main study: (1) 1 point
prevalence nose and throat swab study: asymptomatic
carriage of bacterial upper respiratory pathogens; (2)
feasibility of direct measures of resistance by nose/throat
swabbing.
1. Point prevalence nose and throat swab study:
asymptomatic carriage of bacterial upper respiratory
pathogens
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This pilot study seeks to assess the prevalence of
common bacterial upper respiratory tract commensals
and pathogens in the nose and throat swabs of general
practice staff and patients attending the GP practice
for consultation with non-infectious conditions; and
the rate of antimicrobial resistance in organisms
isolated. It is not clear whether general practice
settings are more like hospital settings, where staff
can have a higher risk of carriage of resistant
organisms; or more like the community, with staff
having similar carriage and resistance patterns to
asymptomatic adults. Properly addressing this question
will have implications for the sort of infection control
practices necessary in General Practice settings.
Anterior nasal and throat swabs will be taken from
selectively recruited general practice staff and
patients who have consented to be part of the sub-
study. A total of 125 general practice staff and 125
patients across the practice sites will be included.
Various appropriate bacterial media will be used to
capture both potential pathogens and normal flora.
The swabs will be cultured on selective media, such
as mannitol salt agar and MacConkey agar to screen
for Staphylococcus aureus and Gram-negative bacteria
of respiratory pathogens such as Klebsiella pneumoniae
and Pseudomonas aeruginosa [40]. Organisms isolated
will be further evaluated for resistance to commonly
used antibiotics with standard susceptibility testing
Fig. 1 Schedule of enrolment, interventions, and assessments
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[41]. Antibiotic resistant organisms will also undergo
molecular characterisation to look for potential
clonality and spread in the community [42].
2. Rolling out community antibiotic resistance
surveillance: ASPReN pilot
The study will assess the feasibility of surveillance of
antibiotic resistance in primary care on a national
basis utilising the Australian Sentinel Practice
Network (ASPReN). ASPReN is a national network
of GPs involved in surveillance activities including
influenza. ASPReN will identify general practices in
their network and provide simple instructions for
taking and transporting throat and nasal swabs
(Fig. 1). ASPReN will provide feedback about the
feasibility of this surveillance activity.
The ASPReN network will select 10 practices across
Australia and each practice will identify five different
patients who present with a non-infectious illness. The
GPs will obtain consent and collect a throat and nose
swab from each patient (for a total of 50 anterior nasal
and 50 throat swabs). The swabs will be processed as
described above.
Ethics
Ethical approval has been obtained for the study from
the University of Queensland (ref: 2015000988). In
addition, administrative review has been obtained from
Bond University and Queensland University of Technology
ethics committees. The Department of Human Services has
granted approval for consent to be obtained from the GPs
to access their Medicare data (ref: MI4140).
Trial status
This project has recruited the 28 GP practices and 110
GPs have consented to us accessing their Medicare data.
The practices have been randomised to the intervention
and control groups. Research coordinators have been
appointed and trained in the interventions during the
initiation phase of the study. The six month study period
is currently underway.
Discussion
This project will test evidence-based approaches de-
signed to improve AMS in general practice settings in
Australia. Each of the interventions has been demon-
strated to be effective on its own at reducing antibiotic
prescribing for ARIs elsewhere in the world [33], how-
ever, this is the first time that they have been combined
into an integrated, multifaceted package, and delivered
as an AMS toolkit. GPs’ antibiotic prescribing rates will
be evaluated to estimate the effectiveness of the package.
Its acceptability and feasibility from the GPs perspective
will be evaluated, including obtaining feedback about
how it may need to be further adapted for the Australian
context. Currently there is limited information about the
cost and cost effectiveness of AMS interventions, as most
have not been evaluated or only looked at in a hospital
context [43]. In undertaking an economic evaluation of
our package to determine the costs of implementation and
weigh these costs against the likely effect, we will provide
important information on its relative efficiency. This kind
of information is vital to decision makers seeking to design
an efficient approach to AMS and maximise the benefits
from recent investment in this area [17].
The sub-studies nested within the main trial will also
add significantly to the knowledge base about antimicrobial
resistance in the GP setting. There are very few data about
community antibiotic resistance surveillance in non- infec-
tious patients and staff. Colonisation with Staphylococcus
aureus has been highly associated with the infections by S.
aureus strains. In an Australian study, the rate of S. aureus
colonisation amongst patients with blood stream infections
by S. aureus was 58 % [44]. The majority of the S. aureus
colonisation was in the nose (80 %). S. aureus colonisation
in the throat was also common (24 %) in that study [44].
Approximately 15 % of S. aureus isolated from these
patients were methicillin resistant S. aureus [44]. Thus
far, there are no Australian data of K. pneumoniae and
P. aeruginosa nasal carriage, the two important Gram-
negative pathogens. P. aeruginosa intestinal carriage has
been recently established [45].
The results on the effectiveness, cost-effectiveness, ac-
ceptability and feasibility of this package of interventions
will support methods of operationalising an integrated
AMS package in an Australian context in order to pro-
mote enhanced AMS initiatives.
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